7-Butoxy-1,2,4-trimethylphenothiazin-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 7-Butoxy-1,2,4-trimethylphenothiazin-3-one
• 英文别名: 7-butoxy-1,2,4-trimethylphenothiazin-3-one
• 化学式: C₁₉H₂₁NO₂S
• 分子量: 327.4
• InChiKey: IQCGXGAWAATLFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS<br/>[FR] DÉRIVÉS DE PHÉNAZINE-3-ONE ET DE PHÉNOTHIAZINE-3-ONE POUR LE TRAITEMENT DE TROUBLES DU STRESS OXYDATIF
  申请人：EDISON PHARMACEUTICALS INC

  公开号：WO2014145119A1

  公开（公告）日：2014-09-18

  Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

  本文披露了苯并咪唑-3-酮和苯并噻唑-3-酮衍生物化合物以及使用这些化合物治疗或抑制氧化应激性疾病的方法，包括线粒体疾病、能量处理障碍、神经退行性疾病和衰老疾病。
• US20140275045A1
  申请人：——

  公开号：US20140275045A1

  公开（公告）日：2014-09-18
• PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
  申请人：EDISON PHARMACEUTICALS, INC.

  公开号：US20160039776A1

  公开（公告）日：2016-02-11

  Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.
• THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF
  申请人：Stealth BioTherapeutics Corp

  公开号：US20160228491A1

  公开（公告）日：2016-08-11

  Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .